BUZZ - UBS raises AbbVie’s target price, citing expansion of its core business beyond the immunology drug sector
路透社2026/10/09 15:01On October 9, UBS raised its target price for AbbVie (ABBV.N) from $260 to $275, stating that investors' focus is shifting from blockbuster drugs Skyrizi and Rinvoq to the next wave of growth in its immunology business. UBS also noted that other projects in AbbVie’s R&D pipeline remain robust. It expects strong third-quarter performances from Skyrizi and Rinvoq, with respective sales reaching $5.7 billion and $2.7 billion. Special attention was given to upcoming combined treatment data of Skyrizi for Crohn's disease and ulcerative colitis, with mid-stage trial results to be released later this month. UBS believes that the drug lutikizumab, for inflammatory skin diseases, has a potential market size of $1-2 billion, and pointed out that Rinvoq sales are likely to surpass $500 million. The report also mentioned positive late-stage clinical data for cancer drugs Epkinly and etentamig, as well as the recent launch of the Parkinson’s disease medication tavapadon. UBS expects third-quarter earnings per share (EPS) to reach $3.76, within AbbVie’s forecast range of $3.73 to $3.77. Including intraday fluctuations, AbbVie’s stock has risen 21% so far this year. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. Due to potential inaccuracies or lack of required context in automated translations, Reuters does not guarantee the accuracy of these texts and is not liable for any damage or loss arising from their use. The translations are provided solely for readers' convenience.)
October 9 - ** UBS raises AbbVie (ABBV.N) price target from $260 to $275
** States that investor focus is shifting from blockbuster drugs Skyrizi and Rinvoq to the next wave of growth in the immunology business; notes that other projects in the R&D pipeline continue to show strong momentum
** Expects Skyrizi and Rinvoq to perform strongly in the third quarter, with sales projected to reach $5.7 billion and $2.7 billion, respectively
** Highlights upcoming data on Skyrizi's use in the combined treatment of Crohn's disease and ulcerative colitis, with mid-term trial results to be released later this month
** Believes that the drug lutikizumab for treating inflammatory skin diseases has a potential market size of $1 billion to $2 billion; points out that Rinvoq sales are likely to exceed $500 million
** Mentions positive late-stage clinical data for the cancer drugs Epkinly (link) and etentamig, as well as the recent launch of the Parkinson's disease treatment tavapadon (link)
** Expects third-quarter earnings per share (EPS) of $3.76, within AbbVie's forecast range of $3.73 to $3.77
** Including intraday fluctuations, the stock has risen 21% since the beginning of the year
(To facilitate non-English speakers, Reuters automates the translation of its reports into several other languages. As automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of the translated text, which is provided solely for reader convenience. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - JPMorgan upgrades VF Corp to "Neutral," shares rise
On October 9, shares of clothing retailer VF Corp (VFC.N) rose about 3% to $14.90 after JPMorgan upgraded its rating from "Underweight" to "Neutral" while maintaining a price target of $18. The brokerage stated that VF's sales and profit in fiscal 2027 are likely to meet or exceed market consensus, with growth expected to be mainly driven by outdoor brands—The North Face, Timberland, and Altra. JPMorgan also noted that the decline in the Vans brand has been brought under control and that wholesale orders for spring 2027 offer "high visibility" for improved performance in the second half of the year. The company is still expected to achieve an operating profit margin of about 10% in fiscal 2029, driven by more full-price sales, better inventory planning, and a shift towards high-margin brands and premium products. Out of 25 brokerages, 8 have a "buy" or more bullish rating, 15 rate it as "hold," and 2 as "sell;" the median price target is $16, according to data compiled by LSEG. As of the previous trading day's close, the stock had fallen about 20% year to date.
University of Michigan October Consumer Sentiment Index falls to a five-month low, with the Current Economic Conditions Indicator hitting a historic low
The University of Michigan’s Consumer Sentiment Index for October dropped to 46.3, below the market expectation of 47.6. The component reflecting current economic conditions decreased to 44.7, setting a new historical low, while the expectations component edged up to 47.3, marking its first rebound since July. Consumers’ one-year inflation expectations rose to 4.7%, and five-to-ten-year inflation expectations increased to 3.5%. According to the survey director, consumers from different political parties agree that the economic outlook has weakened compared to the beginning of the year.
WTI holds steady as traders weigh US-Iran tensions and supply risks
Crypto prices
More
